ViCentra has appointed Reman McDonagh as vice president, global marketing to support the European scale-up of its Kaleido insulin patch pump system and preparations for next-generation launches. The appointment strengthens the company’s leadership team as it advances commercial execution across key European markets and plans for entry into the US.

McDonagh brings more than 20 years of experience in diabetes and medical device commercialization, spanning early-stage innovation through large-scale international growth. She has held leadership roles at Roche, Medtronic, Cellnovo, and Insulet, overseeing brand strategy, go-to-market planning, market development, and major product launches in established and high-growth markets.

“Reman joins ViCentra at a pivotal stage as we transition from strong early traction to disciplined, scalable growth,” said Tom Arnold, chief executive officer of ViCentra. “She brings a rare combination of deep diabetes expertise, end-to-end marketing leadership, and operational rigor, as we strengthen our presence in key European markets and prepare for US market entry.”

Most recently, McDonagh held senior international marketing leadership roles at Insulet, leading the direct launch of Omnipod DASH across 12 European countries and shaping the European launch strategy for Omnipod 5. In her new role, she will lead global marketing strategy, strengthen Kaleido’s value proposition, accelerate demand generation in priority European markets, and drive cross-functional readiness for upcoming product launches.

“Kaleido is a differentiated insulin delivery system, and ViCentra has built meaningful momentum through a clear focus on the user experience,” said McDonagh. “I’m excited to join the team as we scale in key markets and prepare for the next generation of Kaleido, bringing greater choice, flexibility, and freedom to more people living with diabetes.”

McDonagh holds a PhD in chemistry and has led international teams across marketing, market development, and commercial strategy, supporting business units exceeding $400 million in annual revenue. Her appointment follows a series of senior commercial leadership additions at ViCentra, reflecting the company’s commitment to building a world-class team capable of executing long-term growth strategy and delivering impact for people living with diabetes.